Increased neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios can be used to distinguish ovarian masses

Objective: The present study aimed to determine whether platelet count, neutrophil-to-lymphocyte ratio (NLR), and platelet-tolymphocyte ratio (PLR) can be used to distinguish between benign and malignant ovarian lesions. Materials and Methods: This is a retrospective review of 200 women who underwent laparoscopy or laparotomy due to adnexal masses at the Gynecology Department of the study center between January 2012 and January 2015. Results: Ovarian endometrioma was detected in 58 patients (29.0%), epithelial ovarian cancer was diagnosed in 57 patients (28.5%), benign ovarian tumors (serous cystadenoma and mucinous cystadenoma) were identified in 44 patients (22.0%), and dermoid cysts were found in 41 patients (20.5%). When compared to the patients with ovarian endometrioma, the patients with ovarian cancer had significantly older age (p = 0.001), higher NLR (p = 0.003), and higher platelet count (p = 0.001). The women with ovarian cancer had significantly lower lymphocyte count (p = 0.012), higher PLR (p=0.001), and higher serum CA-125 concentrations (p = 0.001) than the women with benign ovarian tumors. The cut-off value of 338,500/mm³ for platelet count had a sensitivity of 95% and specificity of 85% in predicting ovarian cancer. The cut-off value of 3.75 for NLR had a sensitivity of 85% and specificity of 88% in predicting ovarian cancer. The cut-off value of 182.9 for PLR had a sensitivity of 88% and specificity of 82% in predicting ovarian cancer. Conclusion: The elevated thrombocyte count, NLR, and PLR values can be used to distinguish between benign and malignant ovarian lesions.

Adnexal mass; Epithelial ovarian cancer; Neutrophil-to-lymphocyte ratio; Platelet count; Platelet-to-lymphocyte ratio.

[1] Siegel R.L., Miller K.D., Jemal A.: “Cancer statistics, 2016”. CA Cancer J. Clin., 2016, 66, 7.

[2] Ebell M.H., Culp M.B., Radke T.J.: “A systematic review of symptoms for the diagnosis of ovarian cancer”. Am. J. Prev. Med., 2015, 50, 384.

[3] Sundar S., Neal R.D., Kehoe S.: “Diagnosis of ovarian cancer”. BMJ, 2015, 351, h4443.

[4] Grivennikov S.I., Greten F.R., Karin M.: “Immunity, inflammation, and cancer”. Cell, 2010, 140, 883.

[5] Dumitru C.A., Lang S., Brandau S.: “Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression”. Semin. Cancer Biol., 2013, 23, 141.

[6] Landsberg J., Tüting T., Barnhill R.L., Lugassy C.: “The role of neutrophilic inflammation, angiotropism, and pericytic mimicry in melanoma progression and metastasis”. J. Invest. Dermatol., 2016, 136, 372.

[7] Nakamura K., Nishida T., Haruma T., Haraga J., Omichi C., Ogawa C., et al.: “Pretreatment platelet-lymphocyte ratio is an independent predictor of cervicalcancer recurrence following concurrent chemoradiation therapy”. Mol. Clin. Oncol., 2015, 3, 1001.

[8] Song A., Eo W., Lee S.: “Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients”. World J. Gastroenterol., 2015, 21, 12410.

[9] Lee S.M., Russell A., Hellawell G.: “Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma”. Korean J. Urol., 2015, 56, 749.

[10] Cohen J.G., Tran A.Q., Rimel B.J., Cass I., Walsh C.S., Karlan B.Y., Li A.J.: “Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival”. Gynecol. Oncol., 2014, 132, 556.

[11] Allensworth S.K., Langstraat C.L., Martin J.R., Lemens M.A., Mc- Gree M.E., Weaver A.L., et al.: “Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer”. Gynecol. Oncol., 2013, 130, 499.

[12] Chen Y., Zhang L., Liu W.X., Liu X.Y.: “Prognostic significance of preoperative anemia, leukocytosis and thrombocytosis in chinese women with epithelial ovarian cancer”. Asian. Pac. J. Cancer Prev., 2015, 16, 933.

[13] Smith R.A., Bosonnet L., Ghaneh P., Sutton R., Evans J., Healey P., et al.: “The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer”. Surgery, 2008, 143, 658.

[14] Kose M., Celik F., Kose S.K., Arioz D.T., Yilmazer M.: “Could the platelet-to-lymphocyte ratio be a novel marker for predicting invasiveness of cervical pathologies?” Asian Pac. J. Cancer Prev., 2015, 16,.

[15] Raungkaewmanee S., Tangjitgamol S., Manusirivithaya S., Srijaipracharoen S., Thavaramara T.: “Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer”. J. Gynecol. Oncol., 2012, 23, 265.

[16] Kokcu A., Kurtoglu E., Celik H., Tosun M., Malatyal1oglu E., Ozdemir A.Z.: “May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer?” Asian Pac. J. Cancer Prev., 2014, 15, 9781.

[17] Acmaz G., Aksoy H., Unal D., Ozyurt S., Cingillioglu B., Aksoy U., Muderris I.: “Are neutrophil/lymphocyte and platelet/lymphocyte ratios associated with endometrial precancerous andcancerous lesions in patients with abnormal uterine bleeding?” Asian Pac. J. Cancer Prev., 2014, 15, 1689.

[18] Kodama J., Miyagi Y., Seki N., Tokumo K., Yoshinouchi M., Kobashi Y., et al.: “Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 1999, 82, 107.

[19] Watanabe T., Shibata M., Nishiyama H., Soeda S., Furukawa S., Gonda K., et al.: “Serum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer”. Oncol. Lett., 2014, 7, 373.

[20] Asher V., Lee J., Innamaa A., Bali A.: “Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer”. Clin. Transl. Oncol., 2011, 13, 499.

[21] Cho H., Hur H.W., Kim S.W., Kim S.H., Kim J.H., Kim Y.T., Lee K.: “Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment”. Cancer Immunol. Immunother., 2009, 58, 15.

[22] Yildirim M., Demir Cendek B., Filiz Avsar A.: “Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios”. Mol. Clin. Oncol., 2015, 3, 317.